**Author details**

Woojeong Kim<sup>1</sup> , Kui Hyun Kang<sup>1</sup> and Jung-Keun Suh2,3\*

\*Address all correspondence to: jksuh@smit.ac.kr


[11] Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;**3**(2):161-172. DOI: 10.4161/

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

http://dx.doi.org/10.5772/intechopen.79107

35

[12] Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. Journal of

[13] De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G(1). The Journal of Biological

[14] Godar M, de Haard H, Blanchetot C, Rasser J. Therapeutic bispecific antibody formats: A patent applications review (1994-2017). Expert Opinion on Therapeutic Patents.

[15] Strohl WR. Current progress in innovative engineered antibodies. Protein & Cell.

[16] Johnson JA. Biologics and Biosimilars: Background and Key Issues. CRS Report.

[17] Crespi-Lofton J, Skelton JB. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. Journal of the American Pharmaceutical Association. 2017;**57**(5):e15-e27. DOI: 10.1016/j.

[18] Peterson J, Budlong H, Affeldt T, Skiermont K, Kyllo G, Heaton A. Biosimilar products in the modern U.S. health care and regulatory landscape. Journal of Managed Care &

[19] U.S. Food and Drug Administration. Biosimilar and Interchangeable Products [Internet]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologic-

[20] Song KE, Byeon J, Moon DB, Kim HH, Choi Y-J, Suh J-K. Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis. Molecules and Cells. 2014;**37**(11):819-

[21] Byeon J, Choi Y-J, Suh J-K. Structural characterization of modification on the interface between a ligand and its receptor for biopharmaceuticals. Receptors & Clinical

[22] Byeon J, Kang KH, Jung H-K, Suh J-K. Assessment for quantification of biopharmaceutical protein using a microvolume spectrometer on microfluidic slides. BioChip Journal.

Specialty Pharmacy. 2017;**23**(12):1255-1259. DOI: 10.18553/jmcp.2017.23.12.1255

Hematology & Oncology. 2015;**8**:130. DOI: 10.1186/s13045-015-0227-0

Chemistry. 2017;**292**(35):14706-14717. DOI: 10.1074/jbc.M117.793497

2017;R44620. Available from: https://fas.org/sgp/crs/misc/R44620.pdf

Applications/Biosimilars/ucm580419.htm [Accessed: 15-04-2018]

826. DOI: 10.14348/molcells.2014.0214

Investigation. 2015;**2**(2):1-5. DOI: 10.14800/rci.536

2017;**11**(1):21-29. DOI: 10.1007/s13206-016-1104-9

2018;**28**(3):251-276. DOI: 10.1080/13543776.2018.1428307

2018;**9**(1):86-120. DOI: 10.1007/s13238-017-0457-8

mabs.3.2.14960

japh.2017.05.014

3 Seoul Media Institute of Technology, Seoul, Republic of Korea

### **References**


[11] Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs. 2011;**3**(2):161-172. DOI: 10.4161/ mabs.3.2.14960

**Author details**

34 Biopharmaceuticals

Woojeong Kim<sup>1</sup>

**References**

10.1016/j.jpba.2016.05.028

DOI: 10.1038/nbt.3040

0929867324666170113112759

Pharmacy. 1989;**46**(11 Suppl 2):S9-S11

2006;**17**:638-642. DOI: 10.1016/j.copbio.2006.10.002

, Kui Hyun Kang<sup>1</sup>

\*Address all correspondence to: jksuh@smit.ac.kr

3 Seoul Media Institute of Technology, Seoul, Republic of Korea

and Jung-Keun Suh2,3\*

1 BIOnSYSTEMS, Research Center, Seongnam-si, Gyeonggi-do, Republic of Korea

2 Immersive Media Lab, Seoul Media Institute of Technology, Seoul, Republic of Korea

[1] Parr MK, Montacir O, Montacir H. Physicochemical characterization of biopharmaceuticals. Journal of Pharmaceutical and Biomedical Analysis. 2016;**130**:366-389. DOI:

[2] The MJ. Human insulin: DNA technology's first drug. American Journal of Hospital

[3] Walsh G. Biopharmaceutical benchmarks 2014. Nature Biotechnology. 2014;**32**:992-100.

[4] Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: Technological advances driving peptides into development. Current Opinion in Biotechnology.

[5] Uhlig T, Kyprianou T, Martinelli FG, Oppici CA, Heiligers D, Hills D, Calvo XR, Verhaert P. The emergence of peptides in the pharmaceuticalbusiness: From exploration to exploitation. EuPA Open Proteomics. 2014;**4**:58-69. DOI: 10.1016/j.euprot.2014.05.003

[6] Jafari R, Zolbanin NM, Rafatpanah H, Majidi J, Kazemi T. Fc-fusion proteins in therapy: An updated view. Current Medicinal Chemistry. 2017;**24**(12):1228-1237. DOI: 10.2174/

[7] Rogstad S, Faustino A, Ruth A, Keire D, Boyne M, Park J.A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications. Journal of the American

[8] Top 20 Drugs in the World 2017 [Internet]. Available from: https://igeahub.com/2017/08/

[9] Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nature Reviews. Drug

[10] Carter PJ, Lazar GA. Next generation antibody drugs: Pursuit of the 'high-hanging fruit. Nature Reviews. Drug Discovery. 2018;**17**(3):197-223. DOI: 10.1038/nrd.2017.227

Society for Mass Spectrometry. 2017;**28**:786-794. DOI: 10.1007/s13361-016-1531-9

08/top-20-drugs-in-the-world-2017/ [Accessed: 01-04-2018]

Discovery. 2013;**12**(4):259-260. DOI: 10.1038/nrd3980


[23] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q5E guideline, Comparability of biotechnological/biological products subject to changes in their manufacturing process. 2004

[35] Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. Journal of Pharmaceutical

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

http://dx.doi.org/10.5772/intechopen.79107

37

[36] Zhang Z, Pan H, Chen X. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrometry Reviews. 2009;**28**(1):147-176. DOI: 10.1002/mas.20190

[37] Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs. 2013;**5**(5):699-710.

[38] Wang B, Gucinski AC, Keire DA, Buhse LF, Boyne MT 2nd. Structural comparison of two anti-CD20 monoclonal antibody drug products using middle-down mass spectrom-

[39] Fornelli L, Ayoub D, Aizikov K, Beck A, Tsybin YO. Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry. Analytical Chemistry. 2014;**86**(6):3005-3012. DOI: 10.1021/ac4036857 [40] Hartman PA, Stodola JD, Harbour GC, Hoogerheide JG. Reversed-phase high-performance liquid chromatography peptide mapping of bovine somatotropin. Journal of

[41] Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. The Journal of Biological Chemistry. 1987;**262**(35):17156-17163. Available from:

[42] Dougherty JJ Jr, Snyder LM, Sinclair RL, Robins RH. High-performance tryptic mapping of recombinant bovine somatotropin. Analytical Biochemistry. 1990;**190**(1):7-20. DOI:

[43] Schär M, Börnsen KO, Gassmann E. Fast protein sequence determination with matrixassisted laser desorption and ionization mass spectrometry. Rapid Communications in

[44] Bongers J, Cummings JJ, Ebert MB, Federici MM, Gledhill L, Gulati D, Hilliard GM, Jones BH, Lee KR, Mozdzanowski J, Naimoli M, Burman S. Validation of a peptide mapping method for a therapeutic monoclonal antibody: What could we possibly learn about a method we have run 100 times? Journal of Pharmaceutical and Biomedical Analysis.

[45] Hernandez P, Müller M, Appel RD. Automated protein identification by tandem mass spectrometry: Issues and strategies. Mass Spectrometry Reviews. 2006;**25**(2):235-254.

[46] Zhang Y, Fonslow BR, Shan B, Baek MC, Yates JR 3rd. Protein analysis by shotgun/bottom-up proteomics. Chemical Reviews. 2013;**113**(4):2343-2494. DOI: 10.1021/cr3003533

Mass Spectrometry. 1991;**5**(7):319-326. DOI: 10.1002/rcm.1290050705

2000;**21**(6):1099-1128. DOI: 10.1016/S0731-7085(99)00181-8

Chromatography. 1986;**360**(2):385-395. DOI: 10.1016/S0021-9673(00)91687-X

http://www.jbc.org/content/262/35/17156.full.pdf

10.1016/0003-2697(90)90126-T

DOI: 10.1002/mas.20068

etry. The Analyst. 2013;**138**(10):3058-3065. DOI: 10.1039/c3an36524g

Sciences. 2015;**104**(6):1866-1884. DOI: 10.1002/jps.24444

DOI: 10.4161/mabs.25423


[35] Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. Journal of Pharmaceutical Sciences. 2015;**104**(6):1866-1884. DOI: 10.1002/jps.24444

[23] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q5E guideline, Comparability of biotechnological/biological products subject to changes in their manufacturing process. 2004 [24] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q6B guideline, Specifications: Test Procedures

[25] International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Q8 R2 guideline, Pharmaceutical development. 2009. Available from: https://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/

[26] Li Y, Champion MM, Sun L, Champion PA, Wojcik R, Dovichi NJ. Capillary zone electrophoresis-electrospray ionization-tandem mass spectrometry as an alternative proteomics platform to ultraperformance liquid chromatography-electrospray ionization-tandem mass spectrometry for samples of intermediate complexity. Analytical

[27] Srebalus Barnes CA, Lim A. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrometry Reviews.

[28] Bondarenko PV, Second TP, Zabrouskov V, Makarov AA, Zhang Z. Mass measurement and top-down HPLC/MS analysis of intact monoclonal antibodies on a hybrid linear quadrupole ion trap-Orbitrap mass spectrometer. Journal of the American Society for

[29] Tran BQ, Barton C, Feng J, Sandjong A, Yoon SH, Awasthi S, Liang T, Khan MM, Kilgour DPA, Goodlett DR, Goo YA. Comprehensive glycosylation profiling of IgG and IgGfusion proteins by top-down MS with multiple fragmentation techniques. Journal of

[30] He L, Anderson LC, Barnidge DR, Murray DL, Hendrickson CL, Marshall AG.Analysis of monoclonal antibodies in human serum as a model for clinical monoclonal Gammopathy by use of 21 tesla FT-ICR top-down and middle-down MS/MS. Journal of the American Society for Mass Spectrometry. 2017;**28**(5):827-838. DOI: 10.1007/s13361-017-1602-6 [31] Thompson NJ, Rosati S, Heck AJ. Performing native mass spectrometry analysis on therapeutic antibodies. Methods. 2014;**65**(1):11-17. DOI: 10.1016/j.ymeth.2013.05.003 [32] Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Van Dorsselaer A, Cianférani S. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies. Journal of Mass Spectrometry. 2015;**50**(2):285-297. DOI: 10.1002/jms.3554

[33] Siuti N, Kelleher NL. Decoding protein modifications using top-down mass spectrom-

[34] Macht M. Top-down characterization of biopharmaceuticals. Trends in Analytical

etry. Nature Methods. 2007;**4**(10):817-821. DOI: 10.1038/nmeth1097

Chemistry. 2013;**48**:62-71. DOI: 10.1016/j.trac.2013.01.016

Mass Spectrometry. 2009;**20**(8):1415-1424. DOI: 10.1016/j.jasms.2009.03.020

and Acceptance Criteria for Biotechnological/Biological Products. 1999

Guidelines/Quality/ Q8\_R1/Step4/Q8\_R2\_Guideline.pdf

Chemistry. 2012;**84**(3):1617-1622. DOI: 10.1021/ac202899p

Proteomics. 2016;**134**:93-101. DOI: 10.1016/j.jprot.2015.10.021

2007;**26**(3):370-388. DOI: 10.1002/mas.20129

36 Biopharmaceuticals


[47] Byeon J, Yim Y-R, Kim H-H, Suh J-K. Structural identification of a non-glycosylated variant at Ser126 for O-glycosylation site from EPO BRP, human recombinant erythropoietin by LC/MS analysis. Molecules and Cells. 2015;**38**(6):496-505. DOI: 10.14348/ molcells.2015.2256

[59] Motoyama A, Venable JD, Ruse CI, Yates JR 3rd. Automated ultra-high-pressure multidimensional protein identification technology (UHP-MudPIT) for improved peptide identification of proteomic samples. Analytical Chemistry. 2006;**78**(14):5109-5118. DOI:

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

http://dx.doi.org/10.5772/intechopen.79107

39

[60] Omamogho JO, Glennon JD. Comparison between the efficiencies of sub-2 μm C18 particles packed in narrow bore columns. Analytical Chemistry. 2011;**83**(5):1547-1556. DOI:

[61] Water TH. Recent innovations in UHPLC columns and instrumentation. Trends in

[62] González-Ruiz V, Olives AI, Martín MA. Core-shell particles lead the way to renewing high-performance liquid chromatography. Trends in Analytical Chemistry. 2015;**64**:17-

[63] Kochling J, Wu W, Hua Y, Guan Q, Castaneda-Merced J. A platform analytical quality by design (AQbD) approach for multiple UHPLC-UV and UHPLC-MS methods development for protein analysis. Journal of Pharmaceutical and Biomedical Analysis.

[64] Ghosh PK. Introduction to Protein Mass Spectrometry. 1st ed. London: Academic Press; 2015. Available from: https://www.sciencedirect.com/science/book/9780128021026 [65] Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006;**312**(5771):

[66] Yu L, Remmele RL Jr, He B. Identification of N-terminal modification for recombinant monoclonal antibody light chain using partial reduction and quadrupole time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry. 2006;**20**(24):3674-

[67] Wang D, Wynne C, Gu F, Becker C, Zhao J, Mueller HM, Li H, Shameem M, Liu YH. Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry.

[68] Colgrave ML, Craik DJ. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: The importance of the cyclic cystine knot. Biochemistry. 2004;**43**(20):5965-

[69] Fass D. Disulfide bonding in protein biophysics. Annual Review of Biophysics. 2012;**41**:

[70] Goyder MS, Rebeaud F, Pfeifer ME, Kálmán F. Strategies in mass spectrometry for the assignment of Cys-Cys disulfide connectivities in proteins. Expert Review of Proteomics.

[71] Wiesner J, Resemann A, Evans C, Suckau D, Jabs W. Advanced mass spectrometry workflows for analyzing disulfide bonds in biologics. Expert Review of Proteomics.

Analytical Chemistry. 2015;**87**(2):914-921. DOI: 10.1021/ac503158g

63-79. DOI: 10.1146/annurev-biophys-050511-102321

2013;**10**(5):489-501. DOI: 10.1586/14789450.2013.837663

2015;**12**(2):115-123. DOI: 10.1586/14789450.2015.1018896

Analytical Chemistry. 2014;**63**:14-20. DOI: 10.1016/j.trac.2014.07.016

10.1021/ac060354u

10.1021/ac102139a

28. DOI: 10.1016/j.trac.2014.08.008

212-217. DOI: 10.1126/science.1124619

3680. DOI: 10.1002/rcm.2790

5975. DOI: 10.1021/bi049711q

2016;**125**:130-139. DOI: 10.1016/j.jpba.2016.03.031


[59] Motoyama A, Venable JD, Ruse CI, Yates JR 3rd. Automated ultra-high-pressure multidimensional protein identification technology (UHP-MudPIT) for improved peptide identification of proteomic samples. Analytical Chemistry. 2006;**78**(14):5109-5118. DOI: 10.1021/ac060354u

[47] Byeon J, Yim Y-R, Kim H-H, Suh J-K. Structural identification of a non-glycosylated variant at Ser126 for O-glycosylation site from EPO BRP, human recombinant erythropoietin by LC/MS analysis. Molecules and Cells. 2015;**38**(6):496-505. DOI: 10.14348/

[48] Wang Y, Li X, Liu YH, Richardson D, Li H, Shameem M, Yang X. Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic

[49] Pace CN, Vajdos F, Fee L, Grimsley G, Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Science. 1995;**4**(11):2411-2423. DOI: 10.1002/

[50] Proc JL, Kuzyk MA, Hardie DB, Yang J, Smith DS, Jackson AM, Parker CE, Borchers CH. A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. Journal of Proteome

[51] Yu YQ, Gilar M, Lee PJ, Bouvier ES, Gebler JC. Enzyme-friendly, mass spectrometrycompatible surfactant for in-solution enzymatic digestion of proteins. Analytical

[52] Han JC, Han GY. A procedure for quantitative determination of tris(2-carboxyethyl) phosphine, an odorless reducing agent more stable and effective than dithiothreitol.

[53] Svoboda M, Meister W, Vetter W. A method for counting disulfide bridges in small proteins by reduction with mercaptoethanol and electrospray mass spectrometry. Journal of

[54] Switzar L, Giera M, Niessen WM. Protein digestion: An overview of the available techniques and recent developments. Journal of Proteome Research. 2013;**12**(3):1067-1077.

[55] Tsiatsiani L, Heck AJ. Proteomics beyond trypsin. The FEBS Journal. 2015;**282**(14):2612-

[56] Bunkenborg J, Espadas G, Molina H. Cutting edge proteomics: Benchmarking of six commercial trypsins. Journal of Proteome Research. 2013;**12**(8):3631-3641. DOI: 10.1021/

[57] Giansanti P, Tsiatsiani L, Low TY, Heck AJ. Six alternative proteases for mass spectrometry-based proteomics beyond trypsin. Nature Protocols. 2016;**11**(5):993-1006. DOI:

[58] Plumb R, Castro-Perez J, Granger J, Beattie I, Joncour K, Wright A. Ultra-performance liquid chromatography coupled to quadrupole-orthogonal time-of-flight mass spectrometry. Rapid Communications in Mass Spectrometry. 2004;**18**(19):2331-2337. DOI:

Analytical Biochemistry. 1994;**220**(1):5-10. DOI: 10.1006/abio.1994.1290

Mass Spectrometry. 1995;**30**:1562-1566. DOI: 10.1002/jms.1190301107

digestion. MAbs. 2016;**8**(8):1477-1486. DOI: 10.1080/19420862.2016.1226715

Research. 2010;**9**(10):5422-5437. DOI: 10.1021/pr100656u

Chemistry. 2003;**75**(21):6023-6028. DOI: 10.1021/ac0346196

molcells.2015.2256

38 Biopharmaceuticals

pro.5560041120

DOI: 10.1021/pr301201x

10.1038/nprot.2016.057

10.1002/rcm.1627

pr4001465

2626. DOI: 10.1111/febs.13287


[72] Gorman JJ, Wallis TP, Pitt JJ. Protein disulfide bond determination by mass spectrometry. Mass Spectrometry Reviews. 2002;**21**(3):183-216. DOI: 10.1002/mas.10025

[83] Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews. Drug Discovery.

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

http://dx.doi.org/10.5772/intechopen.79107

41

[84] Diepold K, Bomans K, Wiedmann M, Zimmermann B, Petzold A, Schlothauer T, Mueller R, Moritz B, Stracke JO, Mølhøj M, Reusch D, Bulau P. Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One. 2012;**7**(1):e30295. DOI: 10.1371/ journal.

[85] Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, Sanglier-Cianferani S. Characterization of therapeutic antibodies and related products. Analytical Chemistry. 2013;**85**:715-

[86] Fekete S, Guillarme D, Sandra P, Sandra K. Chromatographic, electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals.

[87] Rogers RS, Nightlinger NS, Livingston B, Campbell P, Bailey R, Balland A. Development of a quantitative mass spectrometry multiattribute method for characterization, quality control testing and disposition of biologics. MAbs. 2015;**7**:881-890. DOI: 10.1080/19420862

[88] Wang T, Chu L, Li W, Lawson K, Apostol I, Eris T. Application of a quantitative LC–MS multiattribute method for monitoring site-specific glycan heterogeneity on a monoclonal antibody containing two N-linked glycosylation sites. Analytical Chemistry.

[89] Huhn C, Selman MH, Ruhaak LR, Deelder AM, Wuhrer M. IgG glycosylation analysis.

[90] Abès R, Teillaud JL. Impact of glycosylation on effector functions of therapeutic

[91] Sibéril S, Dutertre CA, Fridman WH, Teillaud JL, Fcgamma R. The key to optimize therapeutic antibodies? Critical Reviews in Oncology/Hematology. 2007;**62**(1):26-33. DOI:

[92] Takahashi M, Kuroki Y, Ohtsubo K, Taniguchi N. Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: Their functions and target proteins. Carbohydrate

[93] Abès R, Dutertre CA, Agnelli L, Teillaud JL. Activating and inhibitory Fcgamma receptors in immunotherapy: Being the actor or being the target. Expert Review of Clinical

[94] Zhang Q, Li Z, Wang Y, Zheng Q, Li J. Mass spectrometry for protein sialoglycosylation.

[95] Tharmalingam T, Adamczyk B, Doherty MA, Royle L, Rudd PM. Strategies for the profiling, characterisation and detailed structural analysis of N-linked oligosaccharides.

Glycoconjugate Journal. 2013;**30**(2):137-146. DOI: 10.1007/s10719-012-9443-9

IgG. Pharmaceuticals (Basel). 2010;**3**(1):146-157. DOI: 10.3390/ph3010146

Research. 2009;**344**(12):1387-1390. DOI: 10.1016/j.carres.2009.04.031

Immunology. 2009;**5**(6):735-747. DOI: 10.1586/eci.09.57

Mass Spectrometry Reviews. 2017. DOI: 10.1002/mas.21555

Analytical Chemistry. 2016;**88**:480-507. DOI: 10.1021/acs.analchem.5b04561

2017;**89**:3562-3567. DOI: 10.1021/acs.analchem.6b04856

Proteomics. 2009;**9**(4):882-913. DOI: 10.1002/pmic.200800715

2012;**11**:527-540. DOI: 10.1038/nrd3746

pone.0030295

736. DOI: 10.1021/ac3032355

10.1016/ j.critrevonc.2006.12.003


[83] Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nature Reviews. Drug Discovery. 2012;**11**:527-540. DOI: 10.1038/nrd3746

[72] Gorman JJ, Wallis TP, Pitt JJ. Protein disulfide bond determination by mass spectrometry. Mass Spectrometry Reviews. 2002;**21**(3):183-216. DOI: 10.1002/mas.10025

[73] Lakbub JC, Shipman JT, Desaire H. Recent mass spectrometry-based techniques and considerations for disulfide bond characterization in proteins. Analytical and Bioanalytical

[74] Liu H, May K. Disulfide bond structures of IgG molecules: Structural variations, chemical modifications and possible impacts to stability and biological function. MAbs.

[75] Wu SL, Jiang H, Hancock WS, Karger BL. Identification of the unpaired cysteine status and complete mapping of the 17 disulfides of recombinant tissue plasminogen activator using LC-MS with electron transfer dissociation/collision induced dissociation.

[76] Wu SL, Jiang H, Lu Q, Dai S, Hancock WS, Karger BL. Mass spectrometric determination of disulfide linkages in recombinant therapeutic proteins using online LC-MS with electron-transfer dissociation. Analytical Chemistry. 2009;**81**(1):112-122. DOI: 10.1021/

[77] Xie H, Gilar M, Gebler JC. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. Analytical Chemistry. 2009;**81**(14):5699-5708. DOI:

[78] Xie H, Chakraborty AB, Chen W. Towards fast mapping of protein disulfide bonds: An integrated workflow for automatic assignment of disulfide pairing. In: Proceedings of Practical Applications of Mass Spectrometry in the Biotechnology Industry; 8-10 September 2010; Marina Del Ray. CA: Mass Spec; 2010. p. 107. Available from: http://

[79] Walsh CT, Garneau-Tsodikova S, Gatto GJ Jr. Protein posttranslational modifications: The chemistry of proteome diversifications. Angewandte Chemie (International Ed. in

[80] Li W, Kerwin JL, Schiel J, Formolo T, Davis D, Mahan A, Benchaar SA. Structural elucidation of post-translational modifications in monoclonal antibodies. In: Schiel JE, Davis DL, Borisov OV, editors. State-of-the-art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization: The NIST mAb Case Study. Washington, DC: American Chemical Society; 2015. pp. 119-

[81] Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discovery

[82] Brinks V, Hawe A, Basmeleh AH, Joachin-Rodriguez L, Haselberg R, Somsen GW, Jis5oot W, Schellekens H. Quality of original and biosimilar epoetin products. Pharmaceutical

Chemistry. 2018;**410**(10):2467-2484. DOI: 10.1007/s00216-017-0772-1

Analytical Chemistry. 2010;**82**(12):5296-5303. DOI: 10.1021/ac100766r

www.waters.com/webassets/cms/ library/docs/720003751en.pdf

English). 2005;**44**(45):7342-7372. DOI: 10.1002/anie.200501023

Today. 2010;**15**:773-780. DOI: 10.1016/j.drudis.2010.06.009

Research. 2011;**28**(2):386-393. DOI: 10.1007/s11095-010-0288-2

183. DOI: 10.1021/bk-2015-1201.ch003

2012;**4**(1):17-23. DOI: 10.4161/mabs.4.1.18347

ac801560k

40 Biopharmaceuticals

10.1021/ac900468j


[96] Lauber MA, Yu YQ, Brousmiche DW, Hua Z, Koza SM, Magnelli P, Guthrie E, Taron CH, Fountain KJ. Rapid preparation of released N-glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection. Analytical Chemistry. 2015;**87**(10):5401-5409. DOI: 10.1021/acs.analchem.5b00758

[108] Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. Journal of Pharmaceutical Sciences. 2007;**96**(7):1708-1718. DOI:

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

http://dx.doi.org/10.5772/intechopen.79107

43

[109] Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, Matsumura M, Bondarenko PV. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry.

[110] Yan Y, Wei H, Fu Y, Jusuf S, Zeng M, Ludwig R, Krystek SR Jr, Chen G, Tao L, Das TK. Isomerization and oxidation in the complementarity-determining regions of a monoclonal antibody: A study of the modification-structure-function correlations by hydrogen-deuterium exchange mass spectrometry. Analytical Chemistry.

[111] Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. Journal of Chromatography. B, Biomedical Sciences and

[112] Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharmaceutical Research. 2007;**24**(6):1145-1156. DOI: 10.1007/

[113] Kroon DJ, Baldwin-Ferro A, Lalan P. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharmaceutical Research.

[114] Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies.

[115] Dick LW Jr, Qiu D, Mahon D, Adamo M, Cheng KC. C-terminal lysine variants in fully human monoclonal antibodies: Investigation of test methods and possible causes. Biotechnology and Bioengineering. 2008;**100**(6):1132-1143. DOI: 10.1002/bit.21855 [116] Luo J, Zhang J, Ren D, Tsai WL, Li F, Amanullah A, Hudson T. Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnology and Bioengineering.

[117] Jiang G, Yu C, Yadav DB, Hu Z, Amurao A, Duenas E, Wong M, Iverson M, Zheng K, Lam X, Chen J, Vega R, Ulufatu S, Leddy C, Davis H, Shen A, Wong PY, Harris R, Wang YJ, Li D. Evaluation of heavy-chain C-terminal deletion on product quality and pharmacokinetics of monoclonal antibodies. Journal of Pharmaceutical Sciences.

Analytical Chemistry. 2005;**77**(18):6004-6011. DOI: 10.1021/ac050672d

2012;**109**(9):2306-2315. DOI: 10.1002/bit.24510

2016;**105**(7):2066-2072. DOI: 10.1016/j.xphs.2016.04.027

Applications. 2001;**752**(2):233-245. DOI: 10.1016/S0378-4347(00)00548-X

10.1002/jps.20823

s11095-007-9241-4

1992;**9**(11):1386-1393

2008;**47**(8):2518-2530. DOI: 10.1021/bi7018223

2016;**88**(4):2041-2050. DOI: 10.1021/acs.analchem.5b02800


[108] Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. Journal of Pharmaceutical Sciences. 2007;**96**(7):1708-1718. DOI: 10.1002/jps.20823

[96] Lauber MA, Yu YQ, Brousmiche DW, Hua Z, Koza SM, Magnelli P, Guthrie E, Taron CH, Fountain KJ. Rapid preparation of released N-glycans for HILIC analysis using a labeling reagent that facilitates sensitive fluorescence and ESI-MS detection. Analytical

[97] Reusch D, Haberger M, Falck D, Peter B, Maier B, Gassner J, Hook M, Wagner K, Bonnington L, Bulau P, Wuhrer M. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-part 2: Mass spectrometric meth-

[98] Terashima I, Koga A, Nagai H. Identification of deamidation and isomerization sites on pharmaceutical recombinant antibody using H(2)(18)O. Analytical Biochemistry.

[99] Liu H, Gaza-Bulseco G, Chumsae C. Glutamine deamidation of a recombinant monoclonal antibody. Rapid Communications in Mass Spectrometry. 2008;**22**(24):4081-4088.

[100] Yang H, Zubarev RA. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis. 2010;**31**(11):1764-1772. DOI:

[101] Robinson AB, Scotchler JW, McKerrow JH. Rates of nonenzymatic deamidation of glutaminyl and asparaginyl residues in pentapeptides. Journal of the American Chemical

[102] Scotchler JW, Robinson AB. Deamidation of glutaminyl residues: Dependence on pH, temperature, and ionic strength. Analytical Biochemistry. 1974;**59**(1):319-322. DOI:

[103] Tyler-Cross R, Schirch V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. The Journal of Biological Chemistry. 1991 Nov 25;**266**(33):22549-22556. Available from:

[104] Geiger T, Clarke S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. The Journal of Biological Chemistry. 1987;**262**(2):785-794. Available from:

[105] Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry. 2007;**46**(6):1534-1544. DOI: 10.1021/bi061500t [106] Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody.

Pharmaceutical Research. 2012;**29**(1):187-197. DOI: 10.1007/s11095-011-0534-2

[107] Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. Journal of Pharmaceutical Sciences. 2008;**97**(7):2426-2447. DOI: 10.1002/

Chemistry. 2015;**87**(10):5401-5409. DOI: 10.1021/acs.analchem.5b00758

ods. MAbs. 2015;**7**(4):732-742. DOI: 10.1080/19420862.2015.1045173

2007;**368**(1):49-60. DOI: 10.1016/j.ab.2007.05.012

http://www.jbc.org/content/266/33/22549.full.pdf

http://www.jbc.org/content/262/2/785.full.pdf

DOI: 10.1002/rcm.3831

42 Biopharmaceuticals

10.1002/elps.201000027

Society. 1973;**95**(24):8156-8159

10.1016/0003-2697(74)90040-2

jps.21180


[118] Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 2007;**852**(1-2):250-256. DOI: 10.1016/j.jchromb.2007.01.024

**Section 3**

**Development**


**Section 3**
